Further investigations are needed to explore the exact role of targeting LOX family proteins and MMPs during tumour metastasis and to understand the circumstances under which targeting ECM remodelling may be used as a therapeutic strategy for cancer patients. This evidence concerns the gene LOX and neoplasm.